Explosive disease progression after single-agent b-cell maturation antigen-targeted treatment in multiple myeloma: A report of three cases in Sheikh Shakhbout Medical City

This report reviews the cases of three patients who were diagnosed with multiple myeloma (MM) international scoring system-3, were heavily pretreated, and refractory to CD38 monoclonal antibodies, two proteasome inhibitors, and two immunomodulatory agents. Shortly after starting on belantamab mafodotin, they experienced rapid and explosive clinical, biochemical, and extramedullary disease progression. After belantamab mafodotin as a single agent was withdrawn from the market when it failed to achieve its primary endpoint in late relapsed/refractory (R/R) MM in the DREAMM-3 trial, there could potentially be a place for it in combination therapy in early R/RMM.